--- title: "BeyondSpring (BYSI) news: offering and Nasdaq notice" url: "https://aibio.space/companies/beyondspring/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BYSI offering and Nasdaq notice news: BeyondSpring sets up at-the-market program for up to $11,942,800 in shares. BeyondSpring, Inc." --- BYSI BeyondSpring, Inc. NASDAQ · United States # BeyondSpring (BYSI) news BYSI offering and Nasdaq notice news Mergers · 2026-10-06 ## [BeyondSpring completes sale of subsidiary holding China unit Bulin for non-cash consideration](https://aibio.space/news/beyondspring-completes-sale-subsidiary-holding-china-unit-bulin-non/) BeyondSpring closed the sale of the holding company for its China unit, Bulin, on September 30, 2026. The buyer paid no cash at closing. It took on the China portion of the DUBLIN-4 Phase 3 trial in exchange, and BeyondSpring will receive the clinical data from that work. ## Latest BeyondSpring news 1. 2026-10-06 Mergers [BeyondSpring sells BeyondSpring Ltd. for trial data rights instead of cash](https://aibio.space/news/beyondspring-sells-beyondspring-ltd-trial-data-rights-instead-cash/) BeyondSpring Inc. completed the sale of BeyondSpring Ltd. to Biolin Investment Limited on September 30, 2026. No cash changed hands. The company received a license to China trial data, a funding commitment from the buyer, and a clawback, and it gave up control of SEED Therapeutics. 2. 2026-10-02 Listings [BeyondSpring gets Nasdaq notice after market value falls below $35 million](https://aibio.space/news/beyondspring-gets-nasdaq-notice-after-market-value-falls-below-35/) BeyondSpring Inc. received a Nasdaq letter on September 29, 2026 saying its market value of listed securities has been below $35 million for 30 consecutive business days. It has until March 29, 2027 to regain compliance, and its shares keep trading in the meantime. 3. 2026-09-29 Financings [BeyondSpring sets up at-the-market program for up to $11,942,800 in shares](https://aibio.space/news/beyondspring-sets-up-market-program-up-11-942-800-shares/) BeyondSpring has set up an at-the-market program through Citizens for up to 9,200,000 ordinary shares, capped at $11,942,800 by its public float limit. The prospectus supplement is dated September 29, 2026, and the same day the company agreed to sell its Chinese subsidiary to Biolin Investment Limited. 4. 2026-09-18 Listings [BeyondSpring gets Nasdaq minimum bid price notice, has until March 16, 2027](https://aibio.space/news/beyondspring-gets-nasdaq-minimum-bid-price-notice-has-until-march-16/) Nasdaq told BeyondSpring on September 17, 2026 that its ordinary shares closed below $1.00 for 30 consecutive business days. Trading continues during a 180 calendar day compliance period that ends March 16, 2027. ## BeyondSpring at a glance - **Ticker**: BYSI - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $6.5 million ### Related companies - [Opus Genetics](https://aibio.space/companies/opus-genetics/) NASDAQ: IRD - [Viskase Holdings](https://aibio.space/companies/viskase/) OTC: VISK - [Perrigo Company](https://aibio.space/companies/perrigo/) NYSE: PRGO - [Oncology Pharma](https://aibio.space/companies/oncology-pharma/) OTC: ONPH - [Trafalgar International](https://aibio.space/companies/trafalgar-international/) OTC: TRFA - [BlossomHill Therapeutics](https://aibio.space/companies/blossomhill-therapeutics/) NASDAQ: BLSM - [Collegium Pharmaceutical](https://aibio.space/companies/collegium-pharmaceutical/) NASDAQ: COLL - [Sonoma Pharmaceuticals](https://aibio.space/companies/sonoma-pharmaceuticals/) NASDAQ: SNOA ### Also on NASDAQ - [PMV Pharmaceuticals](https://aibio.space/companies/pmv-pharmaceuticals/) PMVP - [Gelteq](https://aibio.space/companies/gelteq/) GELS - [Cognition Therapeutics](https://aibio.space/companies/cognition-therapeutics/) CGTX - [C4 Therapeutics](https://aibio.space/companies/c4-therapeutics/) CCCC - [Arrowhead Pharmaceuticals](https://aibio.space/companies/arrowhead-pharmaceuticals/) ARWR - [MannKind](https://aibio.space/companies/mannkind/) MNKD ## What BeyondSpring does BeyondSpring is a clinical stage global biopharmaceutical company focused on developing innovative therapies for patients with high unmet medical needs. Its first-in-class lead asset, plinabulin, is a brain-penetrant microtubule modulator that the company says may help mitigate acquired resistance after immune checkpoint inhibitor treatment. Plinabulin has been administered to over 700 cancer patients and is being developed as a pipeline in a drug, including for reducing chemotherapy-induced neutropenia. After a successful Phase 3 study, DUBLIN-3, in non-small cell lung cancer, a confirmatory global Phase 3 study is ongoing in second- and third-line NSCLC with EGFR wild type after progression on prior immune checkpoint inhibitors. The company is also developing three small molecule immune agents at preclinical stages. It founded SEED Therapeutics Inc. and continues to own an equity stake in it. SEED uses targeted protein degradation technology, has advanced a novel RBM39 degrader into Phase 1 clinical studies in January 2026, and partners with Eli Lilly and Co. and Eisai Co., Ltd. | Product or program | What it is | Stage | |---|---|---| | Plinabulin | Brain-penetrant microtubule modulator being developed for NSCLC after checkpoint inhibitor treatment | confirmatory global Phase 3 study in second- and third-line NSCLC with EGFR wild type | | RBM39 degrader (SEED Therapeutics) | Oncology degrader from the SEED targeted protein degradation platform | Phase 1 clinical studies started January 2026 | | Three small molecule immune agents | Immune agents in the company pipeline | preclinical | Summarised from the company's [10-K filed Mar 25, 2026](https://www.sec.gov/Archives/edgar/data/1677940/000117184326001908/bysi20251231_10k.htm). ## BeyondSpring annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$4.4 million](https://www.sec.gov/Archives/edgar/data/1677940/000117184326001908/) | [$2.6 million](https://www.sec.gov/Archives/edgar/data/1677940/000117184326001908/) | | Net income (loss) | [-$1.0 million](https://www.sec.gov/Archives/edgar/data/1677940/000117184326001908/) | [-$11.1 million](https://www.sec.gov/Archives/edgar/data/1677940/000117184326001908/) | | Cash from operations | [-$19.8 million](https://www.sec.gov/Archives/edgar/data/1677940/000117184326001908/) | [-$16.4 million](https://www.sec.gov/Archives/edgar/data/1677940/000117184326001908/) | | Cash and equivalents | [$7.8 million](https://www.sec.gov/Archives/edgar/data/1677940/000117184326005558/) | [$2.9 million](https://www.sec.gov/Archives/edgar/data/1677940/000117184326001908/) | | Short-term investments | [$4.8 million](https://www.sec.gov/Archives/edgar/data/1677940/000117184326005558/) | [$0](https://www.sec.gov/Archives/edgar/data/1677940/000117184326001908/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $2.7 million, plus short-term investments of $3.8 million, $6.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about BeyondSpring Has BeyondSpring raised money recently? Our latest story on this, dated Sep 29, 2026: "BeyondSpring sets up at-the-market program for up to $11,942,800 in shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/beyondspring-sets-up-market-program-up-11-942-800-shares/). Has BeyondSpring received a Nasdaq deficiency notice? Our latest story on this, dated Oct 2, 2026: "BeyondSpring gets Nasdaq notice after market value falls below $35 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/beyondspring-gets-nasdaq-notice-after-market-value-falls-below-35/). What is the ticker symbol of BeyondSpring? BeyondSpring, Inc. trades under the ticker BYSI on NASDAQ. Where is BeyondSpring listed? BeyondSpring, Inc. is listed on NASDAQ. What is the SEC CIK of BeyondSpring? The SEC Central Index Key (CIK) for BeyondSpring, Inc. is 1677940. Its filings are on SEC EDGAR. How many shares does BeyondSpring have outstanding? 41,119,820 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is BeyondSpring listed under? Our directory records BeyondSpring, Inc. under United States. What does BeyondSpring do? Our directory classifies BeyondSpring, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of BeyondSpring? The ISIN recorded for BeyondSpring, Inc. is KYG108301006. Does aibio.space cover BeyondSpring? aibio.space lists BeyondSpring, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What does BeyondSpring develop? BeyondSpring is a clinical stage global biopharmaceutical company focused on developing innovative therapies for patients with high unmet medical needs. Its first-in-class lead asset, plinabulin, is a brain-penetrant microtubule modulator that the company says may help mitigate acquired resistance after immune checkpoint inhibitor treatment. What is Plinabulin from BeyondSpring? Plinabulin: Brain-penetrant microtubule modulator being developed for NSCLC after checkpoint inhibitor treatment Stage: confirmatory global Phase 3 study in second- and third-line NSCLC with EGFR wild type. What is RBM39 degrader (SEED Therapeutics) from BeyondSpring? RBM39 degrader (SEED Therapeutics): Oncology degrader from the SEED targeted protein degradation platform Stage: Phase 1 clinical studies started January 2026. Is BeyondSpring profitable? BeyondSpring, Inc. reported a net loss of $1.0 million for the fiscal year ended Dec 31, 2025, and used $19.8 million of cash in operations, per its annual report to the SEC. How much does BeyondSpring spend on research and development? $4.4 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: BeyondSpring Members talk about BeyondSpring (BYSI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at BeyondSpring, newest first. Each line links the filing it comes from. 1. 2026-10-06 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1677940/000117184326006465/exh_991.htm) 2. 2026-10-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1677940/000117184326006371/f8k_100226.htm) 3. 2026-09-29 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1677940/000114036126037918/ny20082848x1_424b5.htm) 4. 2026-09-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1677940/000117184326006116/f8k_091826.htm) 5. 2026-08-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1677940/000117184326005558/bysi20260630_10q.htm) 6. 2025-04-11 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1677940/000117184325002158/f8k_041025.htm) 7. 2025-02-25 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1677940/000117184325001050/exh_991.htm) 8. 2025-01-28 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1677940/000117184325000457/exh_991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BYSI on TradingView](https://www.tradingview.com/symbols/NASDAQ-BYSI/). ## SEC filings and registration - **SEC name**: BeyondSpring Inc. - **CIK**: 1677940 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BYSI (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NJ, 07932 - **Phone**: 646-528-4184 - **Shares outstanding**: 41,119,820 as of 2026-07-31 (10-Q filed 2026-08-14) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1677940/000117184326006600/f8k_101326.htm) filed 2026-10-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1677940/000117184326006465/f8k_100626.htm) filed 2026-10-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1677940/000117184326006371/f8k_100226.htm) filed 2026-10-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1677940/000117184326006273/f8k_092826.htm) filed 2026-09-29 - [424B5](https://www.sec.gov/Archives/edgar/data/1677940/000114036126037918/ny20082848x1_424b5.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1677940/000117184326006116/f8k_091826.htm) filed 2026-09-18 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1677940/000117184326005879/def14a_090226.htm) filed 2026-09-03 - [10-Q](https://www.sec.gov/Archives/edgar/data/1677940/000117184326005558/bysi20260630_10q.htm) filed 2026-08-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001677940), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details BeyondSpring, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BYSI, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: BeyondSpring, Inc. - **Ticker**: BYSI - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: KYG108301006 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BYSI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/beyondspring/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BeyondSpring (BYSI) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/beyondspring/